Four-weekly Low-dose Gemcitabine and Paclitaxel in Patients With Platinum-resistant Urothelial Cancer and Performance Status 2/3

Araki, Kyohei; Miyata, Yasuyoshi; Nakamura, Yuichiro; Mukae, Yuta; Otsubo, Asato; Yuno, Tsutomu; Mitsunari, Kensuke; Matsuo, Tomohiro; Ohba, Kenkichi; Sakai, Hideki

doi:10.21873/invivo.11725

Cited by 3 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PROMs are important for assessing quality of treatment from a patient perspective (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16). Most earlier reports of quality of treatment relate to the length of hospital stay and perioperative follow-up, often with surgical focus and lack of information on the patient's own experience.…”

Section: Discussionmentioning

confidence: 99%

“…The Short Form Health Survey (SF-36) allow various disease states and surgical methods to be evaluated (1-13), including cholecystectomy. Several studies have evaluated the SF-36 in benign disease and in patients with cancer following surgery (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13). The RAND-36-Item Health Survey (RAND-36) includes the same set of eight domains as the SF-36, namely General Health (GH), Physical Functioning (PF), Mental Health (MH), Social Functioning (SF), Vitality, Bodily Pain (BP), Role-Physical (RP) and Role-Emotional, however, the scoring of GH and BP scales differs slightly in RAND-36 (14)(15)(16)(17).…”

mentioning

confidence: 99%

See 1 more Smart Citation

First RAND-36-Item Health Survey in Three-dimensional Laparoscopy Cholecystectomy: A Prospective Randomized Study

Eskelinen¹,

Repo²,

Saimanen³

et al. 2023

In Vivo

View full text Add to dashboard Cite

Background/Aim: National healthcare organizers require feedback from patients to improve medical treatment methods. Three-dimensional laparoscopy cholecystectomy (3D-LC) is a modern technique in surgery. However, there are no studies with patient feedback from validated questionnaires assessing the postoperative treatment results in 3D-LC. Patients and Methods: Initially 200 patients with symptomatic cholelithiasis were randomized into 3D-LC or minilaparotomy cholecystectomy (MC) groups. RAND-36-Item Health Survey was performed preoperatively and 4 weeks following surgery relating the survey scores between the 3D-LC and MC groups. Results: Similar postoperative RAND-36 scores were reported for both groups preoperatively and at 4 weeks following surgery, and no significant differences in RAND-36 domains were shown. When the patients in both study groups were combined, Mental Health (p<0.001), Bodily Pain (p=0.01) and General Health (p=0.016) domain scores were significantly higher, indicating a significantly positive change in quality of life 4 weeks postoperatively, while those for the Role-Physical domain were significantly lower, indicating reduced physical activity during the 4 weeks following surgery. In comparison to the Finnish reference RAND-36 scores, scores at 4 weeks were significantly higher for the Mental Health domain (MC group, p=0.001) whilst scores were significantly lower in four other domains : Physical Functioning, Social Functioning, Bodily Pain and Role-Physical. Conclusion: This study shows, for the first time using the RAND-36-Item Health Survey, relatively similar short-term outcomes in patients 4 weeks following cholecystectomy by 3D-LC and MC. Although scores for three RAND-36 domains were significantly higher postoperatively, indicating a significantly positive change in quality of life, a longer follow-up after cholecystectomy is needed for final conclusions to be drawn.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

First RAND-36-Item Health Survey in Three-dimensional Laparoscopy Cholecystectomy: A Prospective Randomized Study

Eskelinen¹,

Repo²,

Saimanen³

et al. 2023

In Vivo

View full text Add to dashboard Cite

show abstract

“…1). For example, βIII-tubulin overexpression has been associated with a poor response to MTAs as well as a shorter overall and progression-free survival in lung (35)(36)(37)(38), ovarian (39)(40)(41)(42), breast (43), prostate (44), urothelial/bladder (45,46), gastric (47,48), and rectal cancers (49), as well as esophageal squamous cell carcinoma (50), pancreatic ductal carcinoma (51), and thymic carcinoma (52) (Fig. 1).…”

Section: βIii-tubulin Associations With Cancermentioning

confidence: 99%

βIII-tubulin overexpression in cancer: Causes, consequences, and potential therapies

Kanakkanthara

Miller

2021

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

“…Paclitaxel is a member of the taxane group of chemotherapeutic agents that induce cell death via inhibition of microtubules in cancer cells. It is part of the standard regimen and clinical trials in various types of cancers [ 44 , 51 , 52 ]. The primary source of paclitaxel-induced ROS production has been identified to be mitochondria [ 53 ].…”

Section: Chemical Compoundsmentioning

confidence: 99%

Pathological and Pharmacological Roles of Mitochondrial Reactive Oxygen Species in Malignant Neoplasms: Therapies Involving Chemical Compounds, Natural Products, and Photosensitizers

et al. 2020

Self Cite

View full text Add to dashboard Cite

Oxidative stress plays an important role in cellular processes. Consequently, oxidative stress also affects etiology, progression, and response to therapeutics in various pathological conditions including malignant tumors. Oxidative stress and associated outcomes are often brought about by excessive generation of reactive oxygen species (ROS). Accumulation of ROS occurs due to dysregulation of homeostasis in an otherwise strictly controlled physiological condition. In fact, intracellular ROS levels are closely associated with the pathological status and outcome of numerous diseases. Notably, mitochondria are recognized as the critical regulator and primary source of ROS. Damage to mitochondria increases mitochondrial ROS (mROS) production, which leads to an increased level of total intracellular ROS. However, intracellular ROS level may not always reflect mROS levels, as ROS is not only produced by mitochondria but also by other organelles such as endoplasmic reticulum and peroxisomes. Thus, an evaluation of mROS would help us to recognize the biological and pathological characteristics and predictive markers of malignant tumors and develop efficient treatment strategies. In this review, we describe the pathological significance of mROS in malignant neoplasms. In particular, we show the association of mROS-related signaling in the molecular mechanisms of chemically synthesized and natural chemotherapeutic agents and photodynamic therapy.

show abstract

Four-weekly Low-dose Gemcitabine and Paclitaxel in Patients With Platinum-resistant Urothelial Cancer and Performance Status 2/3

Cited by 3 publications

References 29 publications

First RAND-36-Item Health Survey in Three-dimensional Laparoscopy Cholecystectomy: A Prospective Randomized Study

First RAND-36-Item Health Survey in Three-dimensional Laparoscopy Cholecystectomy: A Prospective Randomized Study

βIII-tubulin overexpression in cancer: Causes, consequences, and potential therapies

Pathological and Pharmacological Roles of Mitochondrial Reactive Oxygen Species in Malignant Neoplasms: Therapies Involving Chemical Compounds, Natural Products, and Photosensitizers

Contact Info

Product

Resources

About